v3.26.1
Balance Sheet
Dec. 31, 2025
USD ($)
Current assets  
Cash $ 515,931
Due from Sponsor 8,304
Prepaid expenses 212,058
Total current assets 736,293
Long Term prepaid insurance 146,136
Marketable securities held in Trust Account 348,366,162
Total Assets 349,248,591
Current liabilities  
Accrued expenses 16,168
Accrued offering costs 85,000
Total current liabilities 101,168
Advisory Fee Payable 10,350,000
Deferred underwriting fee payable 10,350,000
Total Liabilities 20,801,168
Commitments and Contingencies
Class A ordinary shares subject to possible redemption, $0.0001 par value; 34,500,000 shares at redemption value of approximately $10.10 per share at December 31, 2025 348,366,162
Shareholders' Deficit  
Preference shares, $0.0001 par value; 5,000,000 shares authorized; none issued or outstanding at December 31, 2025 0
Additional paid-in capital 0
Accumulated deficit (19,920,235)
Total Shareholders' Deficit (19,918,739)
Total Liabilities, Class A Ordinary Shares Subject to Possible Redemption, and Shareholders' Deficit 349,248,591
Common Class A [Member]  
Current liabilities  
Class A ordinary shares subject to possible redemption, $0.0001 par value; 34,500,000 shares at redemption value of approximately $10.10 per share at December 31, 2025 348,366,162
Shareholders' Deficit  
Ordinary shares 18
Common Class B [Member]  
Shareholders' Deficit  
Ordinary shares $ 1,478 [1],[2]
[1] Includes 1,928,571 Class B ordinary shares that were subject to forfeiture if the over-allotment option was not exercised in full or in part by the underwriters. Subsequently, on September 29, 2025, the underwriters exercised their over-allotment option in full as part of the closing of the Initial Public Offering. As such, the 1,928,571 founder shares are no longer subject to forfeiture (see Note 5).
[2] On September 25, 2025, the Company issued an additional 2,464,285 founder shares to the Sponsor through share capitalization. As a result, the Sponsor holds an aggregate of 14,785,714 founder shares. All share and per share amounts have been retroactively presented (see Note 5).